Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ
Tumour-infiltrating lymphocytes (TILs) have been demonstrated to significantly influence prognosis and response to therapy of invasive breast cancer (IBC). Thus, it has been suggested that TIL density or/and i...
CONCLUSIONS: Routinely performing SLN biopsy for patients undergoing mastectomy for a preoperative diagnosis of DCIS is overtreatment, because the prevalence of SLN metastasis was low. SLN biopsy can be omitted for most patients. In particular, we suggest omitting SLN biopsy for patients who have lesions of ultrasound category 0-3, who have neither a mass nor NMA detected by ultrasound, or whose initial diagnosis was made based on a specimen obtained by methods other than CNB. PMID: 29786772 [PubMed - as supplied by publisher]
ConclusionsThe risk of IHD was lower for women with DCIS allocated to RT compared to non-irradiated women and to the comparison cohort, probably due to patient selection. Comparison of RT by laterality did not show any over-risk for irradiation of the left breast.
Ductal carcinoma in situ is presumably not a metastatic disease: a reply to "Commentary: Wherein the authors attempt to minimize the confusion generated by their study 'Breast cancer mortality after a diagnosis of ductal carcinoma in situ' by several commentators who disagree with them and a few who don't: a qualitative study". Curr Oncol. 2018 Apr;25(2):e183 Authors: Snodgrass BT PMID: 29719444 [PubMed - in process]
Authors: Chaudhry AT, Koulis TA, Speers C, Olson RA Abstract Purpose: The mainstay of treatment for ductal carcinoma in situ (dcis) involves surgery in the form of mastectomy or lumpectomy. Inconsistency in the use of endocrine therapy (et) for dcis is evident worldwide. We sought to assess the variation in et prescribing for patients with dcis across a population-based radiotherapy (rt) program and to identify variables that predict its use. Methods: Data from a breast cancer database were obtained for women diagnosed with dcis in British Columbia from 2009 to 2014. Associations between et use and patient char...
In this study, we sought to evaluate the outcomes for patients diagnosed with DCIS treated using accelerated whole breast RT and concomitant lumpectomy boost following breast conserving surgery.
CONCLUSIONS: Few interventions are currently available. Whilst some findings are encouraging, improvements on patient outcomes are mixed. Further research should focus on the development and evaluation of effective interventions. PMID: 29730304 [PubMed - as supplied by publisher]
Conclusion Risk of interval invasive second breast cancer varies across women and is influenced by characteristics that can be measured at initial diagnosis, treatment, and imaging. Risk prediction models that evaluate the risk of cancers not detected by surveillance mammography should be developed to inform discussions of tailored surveillance. PMID: 29718790 [PubMed - as supplied by publisher]
CONCLUSIONS: With this unbiased study design and representative group of DCIS patients treated by BCS alone, COX-2, HER2, and periductal fibrosis were revealed as promising markers predicting progression of DCIS into iIBC. Validation will be done in independent data sets. Ultimately, this will aid individual risk stratification of women with primary DCIS. PMID: 29685879 [PubMed - as supplied by publisher]
Conclusions: DCIS patients>50 years had lower risk of dying from all causes combined compared with the general female population, which may reflect differences in health behavior. Women with DCIS had higher risk of dying from breast cancer than the general population, but absolute 10-year risks were low.